Korsmeyer–Peppas’ model [Design Issues]

posted by mittyri – Russia, 2018-04-07 01:36 (2296 d 12:45 ago) – Posting: # 18650
Views: 6,163

Hi Helmut,

just want to add regarding

❝ I don’t expect a lag-time. I would rather say that doxo follows Le Chatelier’s principleand is simply driven out from the liposomes due to the concentration gradient (Cliposomes > Cblood).


with a recent paper1
Looks like it follows Korsmeyer–Peppas’ model
Release = (CumReleased)/(FinallyReleased) = k*tn

[image]

I know that's endless in vitro attempt but it confirms your suggestion.

To obtain an indirect estimate of plasma concentrations of free doxorubicin after administration of Liposomal Doxorubicin, the reported ratio between doxorubicinol, the major doxorubicin metabolite, and doxorubicin concentration in plasma after administration of standard doxorubicin can be used.
Based on the measurement of doxorubicinol, which usually represents 40–50% of the free doxorubicin concentrations, plasma concentrations of free doxorubicin after liposomal administration remain very low, approximately 0.25–1.25% of the total measured drug.2


  1. Fateme Haghiralsadat et al. (2017) A comprehensive mathematical model of drug release kinetics from nano-liposomes, derived from optimization studies of cationic PEGylated liposomal doxorubicin formulations for drug-gene delivery, Artificial Cells, Nanomedicine, and Biotechnology, 46:1, 169–177, doi:10.1080/21691401.2017.1304403.
  2. Gabizon, A., Shmeeda, H. & Barenholz, Y. Clin Pharmacokinet (2003) 42: 419–436. doi:10.2165/00003088-200342050-00002.

Kind regards,
Mittyri

Complete thread:

UA Flag
Activity
 Admin contact
23,112 posts in 4,858 threads, 1,644 registered users;
92 visitors (0 registered, 92 guests [including 9 identified bots]).
Forum time: 14:21 CEST (Europe/Vienna)

Statistics means you never have to say you’re certain.    David L. Streiner

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5